Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IMKELDI vs CLOFARABINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Imkelde (imipenem/cilastatin/relebactam) is a combination antibacterial agent. Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Cilastatin inhibits renal dehydropeptidase I, preventing renal metabolism of imipenem. Relebactam is a beta-lactamase inhibitor that protects imipenem from degradation by certain serine beta-lactamases, including KPC and some Amp C enzymes.
Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.
FDA-approved: Treatment of complicated urinary tract infections including pyelonephritis in adults,FDA-approved: Treatment of complicated intra-abdominal infections in adults,FDA-approved: Treatment of hospital-acquired and ventilator-associated bacterial pneumonia in adults,Off-label: Treatment of bacteremia due to susceptible gram-negative pathogens,Off-label: Treatment of infections due to carbapenem-resistant Enterobacteriaceae (CRE)
Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
10 mg orally once daily
52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.
Terminal elimination half-life: 12 hours (range 10-14 hours) in healthy adults; extended to 24-30 hours in moderate renal impairment (Cr Cl 30-50 m L/min). Clinical context: Steady state achieved after 3-4 days. Twice-daily dosing maintains therapeutic levels.
Terminal elimination half-life: 5.2 hours (range 4-6 hours) in adult patients; clinically, this supports a 5-day continuous infusion schedule
Imipenem is metabolized in the kidney by dehydropeptidase I. Cilastatin is a competitive inhibitor of this enzyme and is also partially metabolized renally. Relebactam is minimally metabolized, primarily eliminated unchanged in urine. The combination has a half-life of approximately 1 hour. No significant hepatic metabolism.
Hepatic; primarily metabolized by deamination via cytidine deaminase to 6-ketoclofarabine, a major metabolite. Also undergoes phosphorylation intracellularly. CYP450 involvement is minimal.
Primarily renal excretion of unchanged drug and metabolites; 70% recovered in urine (60% unchanged, 10% as glucuronide conjugate) and 30% in feces (mainly metabolites) over 72 hours.
Renal: 49-60% as unchanged drug; biliary/fecal: minimal (<1%)
98% bound to serum albumin.
47% bound to plasma proteins (primarily albumin)
0.2 L/kg (approx. 14 L in 70 kg adult). Low Vd indicates distribution primarily in extracellular fluid and plasma, consistent with high protein binding and limited tissue penetration.
Vd: 14.6 L/kg (range 10-20 L/kg); indicates extensive extravascular distribution and tissue binding
Oral: 85% (high bioavailability, minimal first-pass metabolism).
IV: 100% (only IV route); oral: not approved
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). Not recommended for severe renal impairment (GFR <30 m L/min).
Clcr ≥ 60 m L/min: no adjustment; Clcr 30-59 m L/min: reduce dose to 39 mg/m^2; Clcr < 30 m L/min: not recommended (no data).
Child-Pugh A: No dose adjustment. Child-Pugh B: 5 mg orally once daily. Child-Pugh C: Not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25% (monitor toxicity); Child-Pugh C: not recommended (no data).
Safety and efficacy not established in pediatric patients.
52 mg/m^2 intravenously over 2 hours daily for 5 days every 28 days (same as adult dosing per body surface area; safety and efficacy established in pediatric patients 1 year and older).
No specific dose adjustment recommended; consider starting at the lower end of the dosing range due to potential age-related renal impairment.
No specific dose adjustment based solely on age; monitor renal function closely due to increased risk of nephrotoxicity; use same dosing as adults with renal adjustment as per GFR.
None. There is no FDA boxed warning for Imkelde.
Clofarabine causes severe bone marrow suppression, including neutropenia, anemia, thrombocytopenia, and increased risk of infection. Hemorrhage and severe infections have been reported. Monitor blood counts regularly.
Hypersensitivity reactions: Serious and occasionally fatal hypersensitivity reactions (including anaphylaxis) may occur. Cross-allergenicity with other beta-lactams.,Seizures: Higher risk in patients with CNS disorders or renal impairment. Dose adjustment for renal function is required.,Clostridioides difficile-associated diarrhea (CDAD): Can range from mild diarrhea to fatal colitis.,Renal impairment: Dose adjustment necessary; monitor renal function.,Development of drug-resistant bacteria: Overuse may promote resistance.,Interference with laboratory tests: May cause positive direct Coombs test.
1) Myelosuppression: monitor CBCs; dose adjustment may be needed. 2) Infections: increased susceptibility. 3) Hemorrhagic cystitis: may occur; manage with hydration and monitoring. 4) Hepatic toxicity: monitor liver function tests; dose reduction in hepatic impairment. 5) Renal toxicity: monitor renal function; dose adjustment for creatinine clearance <60 m L/min. 6) Tumor lysis syndrome: hydrate and use prophylactic allopurinol. 7) Systemic inflammatory response syndrome (SIRS): monitor for signs; discontinue if occurs.
Known hypersensitivity to any component of Imkelde (imipenem, cilastatin, relebactam) or other beta-lactam antibiotics.,Contraindicated in patients with severe hypersensitivity (e.g., anaphylaxis) to any beta-lactam.
Hypersensitivity to clofarabine or any component of the formulation; severe hepatic impairment (Child-Pugh class C); severe renal impairment (creatinine clearance <30 m L/min).
Grapefruit and grapefruit juice increase drug exposure and should be avoided. High-fat meals may slightly increase absorption, but consistent timing with meals is recommended.
Grapefruit and grapefruit juice may affect liver enzymes and should be avoided. No specific food restrictions, but avoid alcohol due to potential hepatotoxicity. Maintain adequate hydration; no other known food interactions.
First trimester: No adequate human data; animal studies show fetal anomalies at maternal toxic doses. Second and third trimesters: Risk of fetal hypoglycemia and hyperinsulinemia due to KATP channel blockade; avoid unless maternal benefit outweighs risk.
Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malformations including neural tube defects, skeletal anomalies, and cardiovascular defects. Second and third trimester exposure may cause fetal myelosuppression, intrauterine growth restriction, and premature delivery.
Excreted in breast milk; M/P ratio unknown. Potential for infant hypoglycemia; use with caution and monitor infant blood glucose.
It is unknown whether clofarabine is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for at least 1 week after the last dose. M/P ratio is not available.
No specific dose adjustments required; pharmacokinetics unchanged in pregnancy based on limited data. Dose adjustment may be needed for renal function changes.
No specific pharmacokinetic studies have been conducted in pregnant women. Dose adjustments based on pregnancy-induced physiologic changes (increased plasma volume, renal clearance) are not established. Use with caution; the lowest effective dose based on tolerability and clinical response is recommended. Close monitoring for toxicity is essential.
Monitor renal function closely; dose adjustment required for Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors unless benefit outweighs risk. Administer with food to reduce GI upset.
Clofarabine is a purine nucleoside antimetabolite used primarily in pediatric relapsed or refractory acute lymphoblastic leukemia (ALL). It is associated with significant myelosuppression; monitor absolute neutrophil count and platelets closely. Capillary leak syndrome and systemic inflammatory response syndrome (SIRS) are rare but serious adverse effects; consider prophylactic corticosteroids. Hepatic veno-occlusive disease (VOD) has been reported, especially in patients with prior stem cell transplant. Administer with adequate hydration and monitor for tumor lysis syndrome.
Take with meals to decrease stomach upset.,Avoid grapefruit juice during treatment.,Report any signs of allergic reaction, such as rash or difficulty breathing, immediately.,Do not drive or operate machinery if you experience dizziness or drowsiness.,Stay hydrated and inform your doctor of any changes in urine output.
Clofarabine is a chemotherapy drug that may lower your blood cell counts, increasing risk of infection, bleeding, and fatigue.,Report any signs of infection (fever, chills, sore throat), unusual bleeding or bruising, or shortness of breath immediately.,Drink plenty of fluids (8-10 glasses per day) to prevent kidney problems and tumor lysis syndrome.,Avoid live vaccines and close contact with people who have recently received oral polio vaccine.,Use effective contraception during treatment and for at least 6 months after the last dose.,Do not breastfeed while taking clofarabine.,You may experience nausea, vomiting, or diarrhea; your doctor can prescribe medications to manage these symptoms.
No interactions on record
"Clofarabine, a purine nucleoside antimetabolite used in hematologic malignancies, may reduce the metabolism of Eltrombopag, a thrombopoietin receptor agonist, via inhibition of UDP-glucuronosyltransferase (UGT) enzymes, particularly UGT1A1 and UGT1A3. This leads to increased systemic exposure of Eltrombopag, potentially elevating the risk of hepatotoxicity (e.g., elevated liver enzymes) and other adverse effects such as thrombosis. Clinical outcomes may include exacerbated liver injury, which is particularly concerning in patients with pre-existing hepatic impairment or those receiving other hepatotoxic agents."
"Concurrent use of clofarabine and mecamylamine may synergistically increase the risk of severe hypotension and syncope. Clofarabine is a purine nucleoside analog that can cause capillary leak syndrome and hypotension, while mecamylamine is a ganglionic blocker that inhibits sympathetic outflow, leading to orthostatic hypotension. The combined hypotensive effects may result in profound blood pressure reduction, dizziness, and potential falls, particularly in patients with impaired cardiovascular function."
"The combination of clofarabine and nifedipine may increase the risk of cardiotoxicity, particularly QT interval prolongation and left ventricular dysfunction. Clofarabine has been associated with pericardial effusion and cardiac tamponade, while nifedipine, a calcium channel blocker, can cause hypotension and reflex tachycardia, potentially compounding hemodynamic stress in patients with compromised cardiac function. Clinical outcomes may include arrhythmias, heart failure exacerbation, or sudden cardiac death, especially in patients with preexisting cardiovascular risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IMKELDI vs CLOFARABINE, answered by our medical review team.
IMKELDI is a Antineoplastic Agent that works by Imkelde (imipenem/cilastatin/relebactam) is a combination antibacterial agent. Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Cilastatin inhibits renal dehydropeptidase I, preventing renal metabolism of imipenem. Relebactam is a beta-lactamase inhibitor that protects imipenem from degradation by certain serine beta-lactamases, including KPC and some Amp C enzymes.. CLOFARABINE is a Antineoplastic Agent that works by Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IMKELDI and CLOFARABINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IMKELDI is: 10 mg orally once daily. The standard adult dose of CLOFARABINE is: 52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IMKELDI and CLOFARABINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IMKELDI is classified as Category C. First trimester: No adequate human data; animal studies show fetal anomalies at maternal toxic doses. Second and third trimesters: Risk of fetal hypoglycemia and hyperinsulinemia d. CLOFARABINE is classified as Category C. Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malf. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.